BACKGROUND: It is well-known that dementia is undiagnosed, resulting in the exclusion of patients without a formal diagnosis of dementia in many studies. Objectives of the present analyses were (1) to determine healthcare resource utilization and (2) costs of patients screened positive for dementia with a formal diagnosis and those without a formal diagnosis of dementia, and (3) to analyze the association between having received a formal dementia diagnosis and healthcare costs. METHOD: This analysis is based on 240 primary care patients who screened positive for dementia. Within the baseline assessment, individual data about the utilization of healthcare services were assessed. Costs were assessed from the perspective of insurance, solely including direct costs. Associations between dementia diagnosis and costs were evaluated using multiple linear regression models. RESULTS: Patients formally diagnosed with dementia were treated significantly more often by a neurologist, but less often by all other outpatient specialists, and received anti-dementia drugs and day care more often. Diagnosed patients underwent shorter and less frequent planned in-hospital treatments. Dementia diagnosis was significantly associated with higher costs of anti-dementia drug treatment, but significantly associated with less total medical care costs, which valuated to be € 5,123 compared, to € 5,565 for undiagnosed patients. We found no association between dementia diagnosis and costs of evidence-based non-medication treatment or total healthcare cost (€ 7,346 for diagnosed vs. € 6,838 for undiagnosed patients). CONCLUSION: There are no significant differences in total healthcare cost between diagnosed and undiagnosed patients. Dementia diagnosis is beneficial for receiving cost-intensive anti-dementia drug treatments, but is currently insufficient to ensure adequate non-medication treatment for community-dwelling patients.
BACKGROUND: It is well-known that dementia is undiagnosed, resulting in the exclusion of patients without a formal diagnosis of dementia in many studies. Objectives of the present analyses were (1) to determine healthcare resource utilization and (2) costs of patients screened positive for dementia with a formal diagnosis and those without a formal diagnosis of dementia, and (3) to analyze the association between having received a formal dementia diagnosis and healthcare costs. METHOD: This analysis is based on 240 primary care patients who screened positive for dementia. Within the baseline assessment, individual data about the utilization of healthcare services were assessed. Costs were assessed from the perspective of insurance, solely including direct costs. Associations between dementia diagnosis and costs were evaluated using multiple linear regression models. RESULTS:Patients formally diagnosed with dementia were treated significantly more often by a neurologist, but less often by all other outpatient specialists, and received anti-dementia drugs and day care more often. Diagnosed patients underwent shorter and less frequent planned in-hospital treatments. Dementia diagnosis was significantly associated with higher costs of anti-dementia drug treatment, but significantly associated with less total medical care costs, which valuated to be € 5,123 compared, to € 5,565 for undiagnosed patients. We found no association between dementia diagnosis and costs of evidence-based non-medication treatment or total healthcare cost (€ 7,346 for diagnosed vs. € 6,838 for undiagnosed patients). CONCLUSION: There are no significant differences in total healthcare cost between diagnosed and undiagnosed patients. Dementia diagnosis is beneficial for receiving cost-intensive anti-dementia drug treatments, but is currently insufficient to ensure adequate non-medication treatment for community-dwelling patients.
Authors: Bernhard Michalowsky; Steffen Flessa; Tilly Eichler; Johannes Hertel; Adina Dreier; Ina Zwingmann; Diana Wucherer; Henriette Rau; Jochen René Thyrian; Wolfgang Hoffmann Journal: Eur J Health Econ Date: 2017-02-03
Authors: May A Beydoun; Alyssa A Gamaldo; Hind A Beydoun; Danielle Shaked; Alan B Zonderman; Shaker M Eid Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Halima Amjad; Quincy M Samus; Jin Huang; Sneha Gundavarpu; Julie P W Bynum; Jennifer L Wolff; David L Roth Journal: J Am Geriatr Soc Date: 2021-11-13 Impact factor: 5.562
Authors: Amy Rosenwohl-Mack; Leslie Dubbin; Anna Chodos; Sarah Dulaney; Min-Lin Fang; Jennifer Merrilees; Elena Portacolone Journal: Innov Aging Date: 2021-01-18
Authors: S Vandepitte; L Van Wilder; K Putman; N Van Den Noortgate; S Verhaeghe; J Trybou; L Annemans Journal: BMC Geriatr Date: 2020-01-16 Impact factor: 3.921